More protein while on GLP-1 meds in midlife women with overweight/obesity

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In this 12-week, parallel-design trial, middle-aged women with overweight or obesity who are starting or already using GLP-1 medicine are randomized to either GLP-1 alone or GLP-1 plus a protein-rich diet. The protein group receives daily servings of pork-based foods designed to provide about 40 g of high-quality protein per day, with recipes to support breakfast and other meals. Outcomes include body composition, eating behavior, appetite, food cravings, food rewards, and overall health and well-being, measured before and after the intervention. Participants continue their prescribed GLP-1 medication throughout the study under physician guidance. The study is conducted at UT Austin and affiliated sites, with collaboration from the National Pork Board.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult women (30-60 years)
* Having overweight or obesity (BMI \>25 kg/m2)
* Prescribed or taking GLP-1 medicine (within 4 weeks) by a physician
* Willing and able to maintain current inactivity patterns throughout the study
* Willing and able to follow all study procedures
* Generally healthy, as assessed from the medical history questionnaire

Exclusion Criteria:

* Adults (\<30 years or \>60 years)
* Having normal weight (BMI \<25 kg/m2)
* Not prescribed GLP-1 medication by a physician
* Those on GLP-1 medication longer than 4 weeks (during time of screening)
* Currently on a high-protein or other specific diet
* Unwilling and/or unable to maintain current inactivity patterns throughout the study
* Unwilling and/or unable to follow all study procedures
* Unwilling and/or unable to eat pork (for the GLP-1 + Protein group)
* Not generally healthy, as assessed from the medical history questionnaire

Where it's running

• Dell Pediatric Research Center
  Austin, Texas, United States Recruiting
• University of Texas at Austin
  Austin, Texas, United States Not yet recruiting

Study contacts

• Study coordinator: Heather Leidy, PhD, FASN
• Email: Heather.Leidy@austin.utexas.edu
• Phone: 5738252620

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.